We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I refuse

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:


We use tools, such as Google Analytics, to track web traffic and verify the effectiveness of our site.


Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h


Clinical trials

  • Ir-CPI

    This First-In-Human (Phase I) study is a double blind, placebo controlled, single ascending dose trial performed in healthy adult male volunteers with Ir-CPI.

    • ClinicalTrials.gov Trial Identifier NCT04653766
    • Recruitment Status Active, not recruiting
    • Primary Completion Date July 18, 2020
    • The primary objectives of the study were to evaluate the safety and tolerability of Ir-CPI.
    • Secondary study objectives included pharmacokinetic (PK) and pharmacodynamic (PD) assessment of Ir-CPI, i.e. the effect on prolongation of the aPTT coagulation parameter and on the inhibition of FXI and FXII activity.
    • Thirty-two (32) healthy adult male volunteers were enrolled in this trial with a ratio 6-active and 2-placebo per dose level.
    • A total of 4 dose levels of Ir-CPI ranging from 1.5 mg/kg up to 9 mg/kg were tested and administered intravenously for a 6-h period of infusion.

Summary of the Clinical Data

Ir-CPI was well tolerated with no dose-limiting toxicities; there were no safety issues, no related serious adverse events nor adverse events of specific interest, i.e. adverse events related to bleeding.

Plasma exposure during infusion (AUC0-6h) and mean peak plasma concentrations increased dose-proportionally. PK profile of escalating single IV infusion doses of Ir-CPI in healthy male participants was characterized by maximum mean plasma concentrations observed at the end of infusion (i.e. 6 hours). Exposure-dependent changes were observed in the PD parameters: prolongation of the aPTT and inhibition of FXI and FXII procoagulant activities. There was a correlation between Ir-CPI plasma concentrations and biological activity.

For more information, please read the Press Release here

A Phase IIa is under preparation for Ir-CPI in patients with spontaneous intracerebral haemorrhage.